Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Iveson · SciRah

Researcher profile · Semantic Scholar

T. Iveson

Share profile

T. Iveson — researcher profile on SciRah

h-index: 48
Works: 165
Citations: 29K

Most-cited papers

Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
G. Argilés, J. Tabernero, R. Labianca, D. Hochhauser +8 more
2020Annals of Oncology1,223 citations Open access
Semantic Scholar
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
J. Primrose, R. Fox, Daniel H. Palmer, H. Malik +83 more
2019The Lancet Oncology1,082 citations Open access
Semantic Scholar
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
A. Grothey, A. Sobrero, A. Shields, T. Yoshino +19 more
2018New England Journal of Medicine851 citations Open access
Semantic Scholar
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
A. Lamarca, D. Palmer, H. Wasan, P. Ross +17 more
2021The Lancet Oncology604 citations Open access
Semantic Scholar
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
J. Primrose, S. Falk, M. Finch-Jones, J. Valle +17 more
2014The Lancet Oncology422 citations Open access
Semantic Scholar
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
G. Middleton, P. Silcocks, T. Cox, J. Valle +29 more
2014The Lancet Oncology330 citations Open access
Semantic Scholar
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
T. Iveson, R. Donehower, I. Davidenko, S. Tjulandin +12 more
2014The Lancet Oncology262 citations
Semantic Scholar
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
T. André, J. Meyerhardt, T. Iveson, A. Sobrero +17 more
2020The Lancet Oncology225 citations Open access
Semantic Scholar
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
J. Bridgewater, S. Pugh, T. Maishman, Z. Eminton +18 more
2020The Lancet Oncology216 citations Open access
Semantic Scholar
Association analyses identify 31 new risk loci for colorectal cancer susceptibility
P. Law, Maria Timofeeva, C. Fernández-Rozadilla, P. Broderick +155 more
2019Nature Communications205 citations Open access
Semantic Scholar
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
J. Bridgewater, Peter Fletcher, D. Palmer, H. Malik +22 more
2022Journal of Clinical Oncology185 citations Open access
Semantic Scholar
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
T. Iveson, R. Kerr, M. Saunders, J. Cassidy +32 more
2018The Lancet Oncology165 citations Open access
Semantic Scholar
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
L. Lee, T. Starkey, M. Ionescu, M. Little +44 more
2022The Lancet Oncology87 citations Open access
Semantic Scholar
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
T. Iveson, A. Sobrero, T. Yoshino, I. Souglakos +18 more
2021Journal of Clinical Oncology84 citations Open access
Semantic Scholar
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
E. Fontana, J. Meyers, A. Sobrero, T. Iveson +20 more
2021Journal of Clinical Oncology81 citations Open access
Semantic Scholar
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
J. van de Haar, Xu-Hui Ma, S. Ooft, Pim W. van der Helm +46 more
2023Nature Medicine80 citations Open access
Semantic Scholar
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer
M. Lawler, D. Alsina, R. Adams, A. Anderson +85 more
2017Gut80 citations Open access
Semantic Scholar
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
G. Folprecht, C. Pericay, M. Saunders, A. Thomas +14 more
2016Annals of Oncology79 citations Open access
Semantic Scholar
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
Q. Shi, A. Sobrero, A. Shields, T. Yoshino +16 more
201774 citations
Semantic Scholar
A new prognostic and predictive tool for shared decision making in stage III colon cancer.
A. Sobrero, A. Puccini, Q. Shi, A. Grothey +7 more
2020European Journal of Cancer61 citations
Semantic Scholar
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
N. Joharatnam-Hogan, F. Cafferty, R. Hubner, D. Swinson +40 more
2019The Lancet Gastroenterology and Hepatology60 citations Open access
Semantic Scholar
Quality of life, long-term survivors and long-term outcome from the ABC-02 study
J. Bridgewater, A. Lopes, D. Palmer, D. Cunningham +6 more
2016British Journal of Cancer55 citations Open access
Semantic Scholar
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors
K. Pennel, Phimmada Hatthakarnkul, C. Wood, Guang-Yu Lian +35 more
2024Journal of experimental & clinical cancer research : CR47 citations Open access
Semantic Scholar
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).
T. Iveson, A. Sobrero, T. Yoshino, I. Sougklakos +15 more
2019Journal of Clinical Oncology41 citations
Semantic Scholar
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study
L. Lee, M. Ionescu, T. Starkey, M. Little +45 more
2022European Journal of Cancer40 citations Open access
Semantic Scholar
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
Min Zhu, Rui Tang, S. Doshi, K. Oliner +6 more
2015British Journal of Cancer40 citations Open access
Semantic Scholar
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
A. Sobrero, A. Grothey, T. Iveson, R. Labianca +10 more
2018Annals of Oncology37 citations Open access
Semantic Scholar
NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.
K. Shiu, Yan-Rong Jiang, M. Saunders, J. Seligmann +14 more
2024Journal of Clinical Oncology35 citations
Semantic Scholar
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
R. Cohen, D. Vernerey, C. Bellera, A. Meurisse +34 more
2020European Journal of Cancer33 citations Open access
Semantic Scholar
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.
L. Lee, M. Tilby, T. Starkey, M. Ionescu +53 more
2022JAMA Oncology31 citations Open access
Semantic Scholar
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
C. Becerra, R. Salazar, R. García-Carbonero, A. Thomas +8 more
2014Cancer Chemotherapy and Pharmacology31 citations
Semantic Scholar
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
T. Iveson, K. Boyd, R. Kerr, J. Robles-Zurita +33 more
2019Health Technology Assessment30 citations Open access
Semantic Scholar
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
C. Gallois, Q. Shi, J. Meyers, T. Iveson +20 more
2022Journal of Clinical Oncology26 citations Open access
Semantic Scholar
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
T. Hickish, J. Cassidy, D. Propper, I. Chau +10 more
2014European Journal of Cancer26 citations
Semantic Scholar
The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer
P. Alexander, A. Roseweir, K. Pennel, H. V. van Wyk +15 more
2020British Journal of Cancer24 citations Open access
Semantic Scholar
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
P. Pucher, S. Rahman, R. Walker, B. Grace +8 more
2020European Journal of Surgical Oncology24 citations Open access
Semantic Scholar
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials
C. Gallois, Q. Shi, L. Pederson, T. André +21 more
2024Journal of Clinical Oncology23 citations Open access
Semantic Scholar
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Anja L. Frei, A. McGuigan, R. Sinha, Faiz Jabbar +23 more
2024The Lancet Oncology23 citations Open access
Semantic Scholar
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
J. Robles-Zurita, K. Boyd, A. Briggs, T. Iveson +33 more
2018British Journal of Cancer22 citations Open access
Semantic Scholar
Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies
Enric Domingo, C. Kelly, Jennifer Hay, O. Sansom +25 more
2024Journal of Clinical Oncology19 citations Open access
Semantic Scholar
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial.
M. Gögenur, Andreas Weinberger Rosen, T. Iveson, R. Kerr +28 more
2024JAMA Surgery17 citations Open access
Semantic Scholar
GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).
T. R. Jeffry Evans, Thomas Aparicio, K. Le Malicot, Kenichi Nakamura +16 more
201617 citations
Semantic Scholar
The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial
A. Lemanska, A. Harkin, T. Iveson, C. Kelly +2 more
2023ESMO Open15 citations Open access
Semantic Scholar
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
C. Stavraka, A. Pouptsis, A. Synowiec, V. Angelis +18 more
2021Clinical colorectal cancer15 citations Open access
Semantic Scholar
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer
A. Roseweir, J. Park, S. ten Hoorn, Arfon G. M. T. Powell +16 more
2020The Journal of Pathology: Clinical Research15 citations Open access
Semantic Scholar
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study
S. Pugh, M. Bowers, A. Ball, S. Falk +19 more
2016British Journal of Cancer15 citations Open access
Semantic Scholar
A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)
T. Starkey, M. Ionescu, M. Tilby, M. Little +63 more
2023Scientific Reports14 citations Open access
Semantic Scholar
The Early Impact of the IDEA Collaboration Results: How the Results Changed Prescribing Practice
T. Iveson, C. Hanna, Poppy Iveson, Sui Zhang +2 more
2021JNCI Cancer Spectrum13 citations Open access
Semantic Scholar
Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer
M. Nowak, Faiz Jabbar, A.-K. Rodewald, L. Gneo +25 more
2024Cell Reports Medicine11 citations Open access
Semantic Scholar
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer
Victoria Gray, S. Briggs, C. Palles, E. Jaeger +20 more
2019Journal of the National Cancer Institute11 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Harkin×16
Invite
A. Harkin — researcher profile on SciRah
S. Falk×12
Invite
S. Falk — researcher profile on SciRah
J. Paul×11
Invite
J. Paul — researcher profile on SciRah
R. Labianca×10
Invite
R. Labianca — researcher profile on SciRah

×10

Invite

T. Yoshino — researcher profile on SciRah

Invite

T. Hickish — researcher profile on SciRah

J. Bridgewater×10

Invite

J. Bridgewater — researcher profile on SciRah

Invite

A. Sobrero — researcher profile on SciRah

M. Saunders×10

Invite

M. Saunders — researcher profile on SciRah

Invite

Q. Shi — researcher profile on SciRah

Invite

R. Kerr — researcher profile on SciRah

Invite

J. Taieb — researcher profile on SciRah